Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cardiology patient page. Statin intolerance.

× No keyword cloud information.

14 in total

1. Alirocumab (Praluent): First in the New Class of PCSK9 Inhibitors.

Authors: Marina Manniello; Michele Pisano
Journal: P T Date: 2016-01

Review 2. Can modulators of apolipoproteinB biogenesis serve as an alternate target for cholesterol-lowering drugs?

Authors: Lynley M Doonan; Edward A Fisher; Jeffrey L Brodsky
Journal: Biochim Biophys Acta Mol Cell Biol Lipids Date: 2018-04-06 Impact factor: 4.698

3. Value of a Hypothetical Pharmacogenomic Test for the Diagnosis of Statin-Induced Myopathy in Patients at High Cardiovascular Risk.

Authors: Dominic Mitchell; Jason R Guertin; Jacques LeLorier
Journal: Mol Diagn Ther Date: 2018-12 Impact factor: 4.074

4. An image-based small-molecule screen identifies vimentin as a pharmacologically relevant target of simvastatin in cancer cells.

Authors: Kathryn P Trogden; Rachel A Battaglia; Parijat Kabiraj; Victoria J Madden; Harald Herrmann; Natasha T Snider
Journal: FASEB J Date: 2018-01-18 Impact factor: 5.191

5. PCSK9 inhibitors and neurocognitive adverse events: exploring the FDA directive and a proposal for N-of-1 trials.

Authors: Kristopher J Swiger; Seth S Martin
Journal: Drug Saf Date: 2015-06 Impact factor: 5.606

6. Guideline-directed statin intensification in patients with new or worsening symptoms of peripheral artery disease.

Authors: Yevgeniy Khariton; Krishna K Patel; Paul S Chan; Yashashwi Pokharel; Jingyan Wang; John A Spertus; David M Safley; William R Hiatt; Kim G Smolderen
Journal: Clin Cardiol Date: 2018-10-19 Impact factor: 2.882

7. How Do PCSK9 Inhibitors Stack Up to Statins for Low-Density Lipoprotein Cholesterol Control?

Authors: Marj P Zimmerman
Journal: Am Health Drug Benefits Date: 2015-11

Review 8. Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering.

Authors: Dhrubajyoti Bandyopadhyay; Kumar Ashish; Adrija Hajra; Arshna Qureshi; Raktim K Ghosh
Journal: J Lipids Date: 2018-03-25

9. Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.

Authors: Max Korman; Torbjørn Wisløff
Journal: Eur Heart J Cardiovasc Pharmacother Date: 2018-01-01

10. Features of Rhabdomyolysis Secondary to Immobility and Statin-Induced Myopathy in a 70-Year-Old Female.

Authors: Arzoo Shahid; Mobassir A Akbar; Madiha Ariff
Journal: Cureus Date: 2020-05-28